{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:27:36Z","timestamp":1782890856133,"version":"3.54.5"},"reference-count":36,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> Proteasome inhibitors are effective in Waldenstr\u00f6m's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor ixazomib combined with rituximab, in patients with relapsed WM. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> We conducted a multicenter phase I\/II trial with ixazomib, rituximab, and dexamethasone (IRD). Induction consisted of eight cycles IRD wherein rituximab was started in cycle 3, followed by rituximab maintenance. Phase I showed feasibility of 4 mg ixazomib. Primary end point for phase II was overall response rate (ORR [\u2265 minimal response]) after induction. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> A total of 59 patients were enrolled (median age, 69 years; range, 46-91 years). Median number of prior treatments was 2 (range, 1-7); 70% had an intermediate or high WM-IPSS (International Prognostic Scoring System for WM) score. After eight cycles, ORR was 71% (42 out of 59) (14% very good partial response [PR], 37% PR, and 20% minor response). Depth of response improved until month 12 (best ORR 85% [50 out of 59]: 15% very good PR, 46% PR, and 24% minor response). Median duration of response was 36 months. The average hematocrit level increased significantly (0.33-0.38 L\/L) after induction ( P &lt; .001). After two cycles of ixazomib and dexamethasone, immunoglobulin M levels decreased significantly (median 3,700-2,700 mg\/dL, P &lt; .0001). Median time to first response was 4 months. Median progression-free survival and overall survival were not reached. After median follow-up of 24 months (range, 7.4-54.3 months), progression-free survival and overall survival were 56% and 88%, respectively. Toxicity included mostly grade 2 or 3 cytopenias, grade 1 or 2 neurotoxicity, and grade 2 or 3 infections. No infusion-related reactions or immunoglobulin M flare occurred with use of subcutaneous rituximab. Quality of life improved significantly after induction. In total, 48 patients (81%) completed at least six cycles of IRD. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> Combination of IRD shows promising efficacy with manageable toxicity in patients with relapsed or refractory WM. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.21.00105","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T19:59:33Z","timestamp":1628884773000},"page":"40-51","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":33,"title":["Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenstr\u00f6m's Macroglobulinemia: Final Analysis of the Phase I\/II HOVON124\/ECWM-R2 Study"],"prefix":"10.1200","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-3802","authenticated-orcid":false,"given":"Marie Jos\u00e9","family":"Kersten","sequence":"first","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2865-7608","authenticated-orcid":false,"given":"Karima","family":"Amaador","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine M. I.","family":"Vos","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-5015","authenticated-orcid":false,"given":"Kazem","family":"Nasserinejad","sequence":"additional","affiliation":[{"name":"Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Kap","sequence":"additional","affiliation":[{"name":"Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1109-931X","authenticated-orcid":false,"given":"Willem","family":"Kraan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0123-9182","authenticated-orcid":false,"given":"Martine E. D.","family":"Chamuleau","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, VU University, Amsterdam and Cancer Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dries","family":"Deeren","sequence":"additional","affiliation":[{"name":"Department of Hematology, AZ Delta, Roeselare, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0771-5231","authenticated-orcid":false,"given":"Lidwine W.","family":"Tick","sequence":"additional","affiliation":[{"name":"Department of Hematology, Maxima Medical Center, Eindhoven, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-0918","authenticated-orcid":false,"given":"Jeanette K.","family":"Doorduijn","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Gent, Gent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara H.","family":"B\u00f6hmer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Haga Teaching Hospital, The Hague, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto D.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Pals","sequence":"additional","affiliation":[{"name":"Department of Pathology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-503862"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742411"},{"key":"b4","first-page":"2772","volume":"130","author":"Meid K","year":"2017","journal-title":"Blood"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4677"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1833.1833"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-566273"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S49187"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0152"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001963"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1649132"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0646"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01102-3"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25730"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-863241"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13794"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-565135"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12102"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.013"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4784"},{"key":"b23","volume-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers P","year":"2001","edition":"3"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.02.012"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3780-y"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-548941"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.6426"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00555"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16168"},{"key":"b31","author":"Crickx E","journal-title":"bioRxiv"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330357"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1038\/nm1763"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP0YGM8BLFYHJY"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404520"},{"key":"b36","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13897"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.21.00105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T11:04:18Z","timestamp":1653822258000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.00105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"alternative-id":["10.1200\/JCO.21.00105"],"URL":"https:\/\/doi.org\/10.1200\/jco.21.00105","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,1]]},"assertion":[{"value":"2021-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}